We Need Your Urgent Help To Sustain This Website And All Our Research And Community Initiatives. Please Help By Donating To Our Cause. Go To The Sponsorship Section.

BREAKING NEWS
Source: Thailand Medical News  Oct 26, 2019  2 years ago
Tesamorelin (Egrifta) Reverses Signs of Liver Disease In Individuals With HIV
Tesamorelin (Egrifta) Reverses Signs of Liver Disease In Individuals With HIV
Source: Thailand Medical News  Oct 26, 2019  2 years ago
Medical researchers from the US National Institutes of Health and the Massachusetts General Hospital (MGH) in Boston report that the injectable hormone tesamorelin (Egrifta) reduces liver fat and prevents liver fibrosis (scarring) in people living with HIV.



Dr Anthony S. Fauci,NIAID Director (NIAID is one of the entities under the  NIH) commented in a phone interview with Thailand Medical News  “Many people living with HIV have overcome significant obstacles to live longer, healthier lives, though many still experience liver disease.It is encouraging that tesamorelin, a drug already approved to treat other complications of HIV, may be effective in addressing non-alcoholic fatty liver disease.”

The findings were published in October in the The Lancet HIV journal.

NAFLD or Non-alcoholic fatty liver disease frequently occurs alongside HIV, affecting as many as 28% of people living with HIV in the developed world. No effective treatments currently exist to treat the condition, which is a risk factor for progressive liver disease and liver cancer.

Medical researchers led by Colleen M. Hadigan, M.D., senior research physician in NIAID’s Laboratory of Immunoregulation, and Steven K. Grinspoon, M.D., Chief of the Metabolism Unit at MGH, tested whether tesamorelin could decrease liver fat in men and women living with both HIV and NAFLD.

Of the participants enrolled, 43% had at least mild fibrosis, and 33% met the diagnostic criteria for a more severe subset of NAFLD called nonalcoholic steatohepatitis (NASH). Thirty-one participants were randomized to receive daily 2-mg injections of tesamorelin, and 30 were randomized to receive identical-looking injections containing a placebo. Researchers then compared measures of liver health in both groups at baseline and 12 months.

After 12 months, participants receiving tesamorelin had better liver health than those receiving placebo, as defined by reduction in hepatic fat fraction (HFF) ie the r atio of fat to other tissue in the liver. The healthy range for HFF is less than 5%. Thirty-five percent of study participants receiving tesamorelin achieved a normal HFF, while only 4% of those on placebo reached that range with nutritional advice alone. Overall, tesamorelin was well-tolerated and reduced participants’ HFF by an absolute difference of 4.1% (corresponding to a 37% relative reduction from the beginning of the study). While nine participants receiving placebo experienced onset or worsening of fibrosis, only two participants in the tesamorelin group experienced the same. Additionally, levels of several blood markers associated with inflammation and liver damage including the enzyme alanine aminotransferase (ALT),decreased more among those taking tesamorelin compared to those on a placebo, particularly among those with increased levels at the beginning of the study.



Considering  these positive results, investigators suggest expanding the indication for tesamorelin to include people living with HIV who have been diagnosed with NAFLD. They also recommend additional research to determine if tesamorelin could contribute to long-term protection against serious liver disease in people without HIV.

Dr Colleen M. Hadigan further commented to Thailand Medical News via phone, “Our hope is that this intervention may help people living with HIV, as well as benefit HIV-negative people with liver abnormalities.Further research may inform us of the potential long-term benefits of this approach and develop formulations that can benefit everyone with liver disease, regardless of HIV status.”

Tesamorelin (Egrifta) was approved in 2010 by the US FDA to reduce excess abdominal fat in HIV patients with lipodystrophy,a complication characterized by an abnormal distribution of body fat initially associated with older classes of HIV medications. The most commonly reported side effects in previous clinical trials evaluating Egrifta included joint pain (arthralgia), skin redness and rash at the injection site (erythema and pruritis), stomach pain, swelling, and muscle pain (myalgia). Worsening blood sugar control occurred more often in trial participants treated with Egrifta than with placebo.

As tesamorelin proved effective in treating abnormal fat build-up in the abdomens of people in the context of HIV and related medication use, the researchers hypothesized that the drug might also reduce fat that accrues in the liver and causes damage in a similar population.

While liver disease is often associated with heavy alcohol use, NAFLD occurs when excess fat builds up in the liver without alcohol as a contributing factor. This condition may progress to liver damage, cirrhosis or cancer that could be life-threatening and necessitate liver transplantation.

Previous studies have found that vitamin E supplements, weight loss and other lifestyle changes can improve outcomes among HIV-negative people with NASH. However, treatment options for NASH and NAFLD are often not tested in people with HIV and none are available for this group. Obesity and type 2 diabetes raise the risk of developing NAFLD regardless of HIV status, and people with HIV are at increased risk of NAFLD because some HIV medications and HIV itself are associated with gaining abdominal fat and may contribute to liver fat build-up.

Individuals living with HIV are advised to have routine liver screenings and if signs of NAFLD or liver fibrosis are developing to consult their doctors about starting Tesamorelin (Egrifta) therapy.

Reference: “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial” by Takara L Stanley, MD; Lindsay T Fourman, MD; Meghan N Feldpausch, ANP; Julia Purdy, CRNP; Isabel Zheng, BS; Chelsea S Pan, BA; Julia Aepfelbacher, BS; Colleen Buckless, MS; Andrew Tsao, BS; Anela Kellogg, MSN; Karen Branch, RN; Hang Lee, PhD; Chia-Ying Liu, MD; Kathleen E Corey, MD; Raymond T Chung, MD; Martin Torriani, MD; Prof David E Kleiner, MD; Colleen M Hadigan, MD and Prof Steven K Grinspoon, MD, 11 October 2019, The Lancet HIVDOI: 10.1016/S2352-3018(19)30338-8

MOST READ

Feb 05, 2020  2 years ago
Source : Thailand Medical news